Drugs / NMS-03592088
NMS-03592088
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03922100 | Apr 2019 → Aug 2024 | acute myeloid leukemia, chronic myelomonocytic leukemia | Nerviano Medical Sciences | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-03-04 | Nerviano Medical Sciences | Regulatory Nerviano Medical Sciences received European Medicines Agency (EMA) Orphan Drug Designation for its next-generation FLT3 inhibitor NMS-03592088 for treatment of Acute Myeloid Leukemia nervianoms.com ↗
Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc. (NMS-US), a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced that European Commission has granted Orphan Drug Designation (ODD) for NMS-03592088 for the treatment of Acute Myeloid Leukemia (AML), just a few weeks after the US Food and Drug Administration (FDA) approval. |
| 2024-01-09 | Nerviano Medical Sciences | Regulatory Nerviano Medical Sciences received Orphan Drug Designation for its next-generation FLT3 inhibitor NMS-03592088 for treatment of Acute Myeloid Leukemia nervianoms.com ↗
Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc. (NMS-US), a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its next-generation FLT3 inhibitor NMS-03592088 for the treatment of Acute Myeloid Leukemia (AML). |
| 2023-06-22 | Nerviano Medical Sciences | Regulatory Nerviano Medical Sciences Announces FDA Clearance of Investigational New Drug (IND) for NMS-03592088 in positive Relapsed or Refractory Acute Myeloid Leukemia nervianoms.com ↗
Nerviano Medical Sciences Srl (NMS), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to announce the FDA Clearance of Investigational New Drug (IND) Application for NMS-03592088 (NMS-088), a novel, potent FLT3 inhibitor. |
| 2023-04-21 | Nerviano Medical Sciences | Results Nerviano Medical Sciences included as AACR 2023 Plenary Session highlights for its NMS-03592088 Phase 1 Clinical Trial Data in Patients with FLT3 positive Relapsed or Refractory Acute Myeloid Leukemia nervianoms.com ↗
NMS-03592088 showed manageable safety with no maximum tolerated dose characterized. |
| 2023-04-16 | Nerviano Medical Sciences | Results Nerviano Medical Sciences Announces Phase 1 Clinical Trial Data for NMS-03592088 in Patients with FLT3 positive Relapsed or Refractory Acute Myeloid Leukemia nervianoms.com ↗
NMS-03592088 showed manageable safety with no maximum tolerated dose characterized. |
All press releases naming this drug 6 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NMS-03592088 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03922100 ↗ |
| Action | Inhibit | “a FLT3, KIT and CSF1R Inhibitor” NCT03922100 ↗ |
| Route | Oral | “Route of administration: Oral” NCT03922100 ↗ |
| Target | CSF1R | “a FLT3, KIT and CSF1R Inhibitor” NCT03922100 ↗ |
| Target | FLT3 | “a FLT3, KIT and CSF1R Inhibitor” NCT03922100 ↗ |
| Target | KIT | “a FLT3, KIT and CSF1R Inhibitor” NCT03922100 ↗ |